[HTML][HTML] Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)
Context Prostate-specific membrane antigen (PSMA) targeting positron emission
tomography (PET) is emerging to become a reference imaging tool for the staging and …
tomography (PET) is emerging to become a reference imaging tool for the staging and …
Radiotheranostics in oncology: making precision medicine possible
EO Aboagye, TD Barwick… - CA: a cancer journal for …, 2023 - Wiley Online Library
A quintessential setting for precision medicine, theranostics refers to a rapidly evolving field
of medicine in which disease is diagnosed followed by treatment of disease‐positive …
of medicine in which disease is diagnosed followed by treatment of disease‐positive …
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman… - European journal of …, 2023 - Springer
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
significant prostate adenocarcinomas, and patients with target-positive disease can easily …
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu] Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate …
Background Previously, results from the TheraP trial showed that treatment with lutetium-177
[177 Lu] Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA) response rate …
[177 Lu] Lu-PSMA-617 improved frequency of prostate-specific antigen (PSA) response rate …
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
WP Fendler, M Eiber, M Beheshti, J Bomanji… - European journal of …, 2023 - Springer
Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …
Response evaluation criteria in PSMA PET/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer
A Gafita, L Djaileb, I Rauscher, WP Fendler… - Radiology, 2023 - pubs.rsna.org
Background Response Evaluation Criteria in Prostate-specific Membrane Antigen (PSMA)
PET/CT (RECIP 1.0) initially integrated software-based quantitative assessment of PSMA …
PET/CT (RECIP 1.0) initially integrated software-based quantitative assessment of PSMA …
[68Ga] Ga-PSMA versus [18F] PSMA positron emission tomography/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review …
L Evangelista, T Maurer, H van der Poel… - European Urology …, 2022 - Elsevier
Context In the past 10 yr, several agents based on prostate-specific membrane antigen
(PSMA) for positron emission tomography imaging have been introduced in clinical practice …
(PSMA) for positron emission tomography imaging have been introduced in clinical practice …
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 …
Abstract Purpose To compare the Response Evaluation Criteria in Solid Tumors (RECIST)
1.1, the adapted Prostate Cancer Working Group Criteria 3 (aPCWG3), the adapted Positron …
1.1, the adapted Prostate Cancer Working Group Criteria 3 (aPCWG3), the adapted Positron …
Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics
V Liberini, R Laudicella, M Balma, DG Nicolotti… - European radiology …, 2022 - Springer
In prostate cancer (PCa), the use of new radiopharmaceuticals has improved the accuracy of
diagnosis and staging, refined surveillance strategies, and introduced specific and …
diagnosis and staging, refined surveillance strategies, and introduced specific and …
[HTML][HTML] Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but various areas of management still lack high …
prostate cancer have improved outcomes, but various areas of management still lack high …